Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter Financial Results on August 11, 2022
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Thursday, August 11, 2022...
Onconova Therapeutics Announces Key Management Promotions
Mark Guerin promoted to Chief Operating Officer and Chief Financial Officer Dr. Adar Makovski Silverstein promoted to Senior Director and Head of...
Onconova Therapeutics Announces Abstract at the ASCO Annual Meeting Highlighting Narazaciclib’s Differentiated Inhibitory and Improved Safety Profile in Preclinical Models
In vitro and cell-based assays suggest narazaciclib’s inhibitory profile may provide safety and efficacy advantages over currently approved CDK4/6...
Onconova Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today...